Sandoz said that the company has acquired distribution rights to the brand and to an authorized generic of Proventil HFA albuterol MDI from Kindeva Drug Delivery and has already launched the generic MDI in the US. Proventil HFA was first marketed in the US by Schering and then by Merck. In April 2019, Par Pharmaceuticals announced that it had launched an authorized generic of Proventil HFA that was being manufactured by 3M (now Kindeva). The Sandoz announcement cites the increased demand for albuterol MDIs due to the COVID-19 pandemic.
Sandoz President Keren Haruvi commented, “With the commercial distribution rights to the brand and authorized generic of Proventil HFA, we are excited to work to increase supply and help ensure patients who need albuterol have access to this important medicine. This deal delivers on our strategy to grow our respiratory portfolio and brings us closer to our ambition to be the world’s leading and most valued generic company.”
Kindeva Drug Delivery CEO Aaron Mann said, “We are pleased to partner with Sandoz on the distribution of the authorized generic of Proventil from our manufacturing site in Northridge, California. Combining Kindeva’s long track record of formulating, developing and manufacturing complex combination drug products with the Sandoz legacy of successfully commercializing critical drug therapies will help more patients access this important medicine.”
Read the Sandoz press release.
